Growth hormone response to apomorphine in panic disorder: comparison with major depression and normal controls.
Several lines of evidence suggest that dopamine might be involved in anxiety states. In the present study we assessed the growth hormone (GH) response to 0.5 mg apomorphine (a dopaminergic agonist) in 10 male drug-free inpatients meeting Research Diagnostic Criteria for panic disorder who were compared with 10 male major depressive inpatients and 10 male normal controls. The three groups differed significantly in the GH peak response (mean +/- SD): 27.8 +/- 12.5 ng/ml in panics, 5.4 +/- 4.0 ng/ml in major depressives, and 25.8 +/- 11.3 ng/ml in normal controls (F(2,27) = 15.3; P = 0.00003). Although there were significant differences between panics and major depressives (P = 0.00004), and between major depressives and controls (P = 0.00004), panics did not significantly differ from controls. These results do not support the hypothesis of an overlap between panic and affective disorders, and suggest that the hypothalamo-GH-somatomedin axis could be intact in panic disorder.
Psychiatric Unit, University Hospital of Liège, Belgium.
W
W
Pichot
M
M
Hansenne
A
A
Gonzalez Moreno
M
M
Ansseau
D000328:Adult; D001058:Apomorphine / Q000494:pharmacology*; D003866:Depressive Disorder / Q000097:blood / Q000175:diagnosis / Q000523:psychology*; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000494:pharmacology*; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D016584:Panic Disorder / Q000097:blood / Q000523:psychology*; D010913:Pituitary-Adrenal System / Q000187:drug effects; D011569:Psychiatric Status Rating Scales; D011863:Radioimmunoassay
D018491:Dopamine Agonists; D013006:Growth Hormone; D001058:Apomorphine; D004298:Dopamine